Plas-Free Ltd
Plas-Free Ltd is a clinical stage HealthTech company specialized in the development and commercialization of vital fluid absorbent devices for blood purification. Founded in 2017, the company focuses on innovative solutions to improve health outcomes and reduce healthcare costs. Their product pipeline aims to address unmet medical needs, particularly in the treatment of massive bleeding and hyperammonemia. The company has demonstrated significant efficacy in reducing bleeding through its ClearPlasma device, which has shown to decrease blood loss by more than 50% in pre-clinical trials.
Industries
Nr. of Employees
small (1-50)
Plas-Free Ltd
Wadi El Haj 13, P.O. Box 1252, Nazareth 17111, Israel
Awards
Fiscal Year 2024 Military Prototype Advancement Initiative (MPAI)
ClearPlasma Filtration System for Improved Clotting
Funding (ceiling)
$3,179,999.74
Award Year
2024
Patents
Extracorporeal device and matrix for removing fibrinolytic proteins from biological fluids, methods and uses thereof
2024-05-07 • US-11975132-B2
View DetailsHuman blood-derived products having decreased fibrinolytic activity and uses thereof in hemostatic disorders
2022-11-08 • US-11491186-B2
View Details
Extracorporeal device and matrix for removing fibrinolytic proteins from biological fluids, methods and uses thereof
2024-05-07 • US-11975132-B2
View DetailsHuman blood-derived products having decreased fibrinolytic activity and uses thereof in hemostatic disorders
2022-11-08 • US-11491186-B2
View DetailsProducts
Single-use affinity-resin plasma filter for selective protein depletion
Sterile, non-pyrogenic, single-use filter that removes a target plasma protein from plasma fractions via an affinity-ligand resin bed to modulate fibrinolytic activity prior to transfusion; designed for compatibility with bedside (on-line) or off-line plasma preparation and to interface with standard apheresis/transfusion workflows.
Single-use adsorption column for ammonia removal from plasma
Sterile, single-use adsorption column engineered to extract ammonia from plasma fractions to reduce plasma ammonia concentration during extracorporeal treatment of acute hyperammonemia or hepatic encephalopathy.
Single-use affinity-resin plasma filter for selective protein depletion
Sterile, non-pyrogenic, single-use filter that removes a target plasma protein from plasma fractions via an affinity-ligand resin bed to modulate fibrinolytic activity prior to transfusion; designed for compatibility with bedside (on-line) or off-line plasma preparation and to interface with standard apheresis/transfusion workflows.
Single-use adsorption column for ammonia removal from plasma
Sterile, single-use adsorption column engineered to extract ammonia from plasma fractions to reduce plasma ammonia concentration during extracorporeal treatment of acute hyperammonemia or hepatic encephalopathy.
Expertise Areas
- Extracorporeal plasma purification and transfusion preparation
- Clinical trial design and execution for medical devices (including randomized controlled trials and DSMB oversight)
- Preclinical hemorrhage and hepatic injury animal models
- Design and manufacture of disposable blood-contacting devices
Key Technologies
- Affinity ligand resin filtration
- Adsorbent resin chemistry for small-molecule removal
- Single-use sterile device construction
- Interfaces for extracorporeal apheresis/transfusion systems
Key People
CMO and Founder
QA Manager
COO
R&D Manager
CMO and Founder
QA Manager
COO
R&D Manager
Investors
European Innovation Council
Announced on 2021-10-06.
European Innovation Council
$1,477,971 funded.
Announced on 2021-10-06.
European Innovation Council
Announced on 2021-10-06.
European Innovation Council
$1,477,971 funded.
Announced on 2021-10-06.
News & Updates
Plas-Free has successfully achieved ISO 13485 certification, confirming its management system for medical devices.
PlasFree won first place in the distinguished ENRICH Funding Summit, showcasing its innovative solutions.
EIC Grant
PlasFree won approximately €1.8M grant and an additional €2.1M investment from the EIC for its innovative proposals.
PlasFree finished second in the MedTech Startup Contest, which includes a clinical trial with The Baruch Padeh Medical Center, Poriya.
Clinical Trial Completion
Plas-Free completed the open label phase evaluating ClearPlasma in upper gastrointestinal bleeding, demonstrating safety and initial efficacy.
Plas-Free Ltd has a patent portfolio that includes three pending patents aimed at protecting its innovative technologies in major markets worldwide.
Plas-Free has successfully achieved ISO 13485 certification, confirming its management system for medical devices.
PlasFree won first place in the distinguished ENRICH Funding Summit, showcasing its innovative solutions.
EIC Grant
PlasFree won approximately €1.8M grant and an additional €2.1M investment from the EIC for its innovative proposals.
PlasFree finished second in the MedTech Startup Contest, which includes a clinical trial with The Baruch Padeh Medical Center, Poriya.
Clinical Trial Completion
Plas-Free completed the open label phase evaluating ClearPlasma in upper gastrointestinal bleeding, demonstrating safety and initial efficacy.
Plas-Free Ltd has a patent portfolio that includes three pending patents aimed at protecting its innovative technologies in major markets worldwide.